Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer

Edyta M. Urbanska, MD, PhD1; Jens B. Sørensen, MD, DMSc1; Linea C. Melchior, PhD2; Junia C. Costa, MD3; and Eric Santoni-Rugiu, MD, PhD2,4

JCO Precis Oncol 6:e2200040. © 2022 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License

Introduction

Although most cases of metastatic non–small-cell lung cancer (NSCLC) harboring EGFR (ex19del or L858R) mutations respond to the EGFR tyrosine kinase inhibitor (TKI) osimertinib, they inevitably become resistant to this drug. The extent of progression-free survival depends on intrinsic or acquired on-target/off-target mechanisms of osimertinib resistance.1-3 In this respect, oncogenic fusions of receptor tyrosine kinases, detectable in 1%-10% of cases of acquired osimertinib resistance, are particularly relevant, as several of them are druggable by specific TKIs.3 Yet, although osimertinib-resistant cases with acquired ALK or ROS1 fusions have shown objective response (OR) to well-established ALK/ROS1-TKIs,4,5 the treatment and outcome of patients acquiring RET fusions during treatment with osimertinib are more difficult to envisage because of variable and rare fusion partners and limited experience with RET-TKIs in this setting. In this study, we describe a patient with disseminated EGFR+-mutated (EGFR+) NSCLC, who progressed on second-line osimertinib acquiring ANK3-RET fusion (not reported before in this setting) together with MDM2 amplification and PTEN mutation. Despite these significant genomic coalterations, the patient has been displaying sustained ongoing OR to the osimertinib-pralsetinib combination for more than 12 months, providing clinical evidence for ANK3-RET fusion as important, effectively targetable mechanism of osimertinib resistance.

Case Report

The patient, a 62-year-old White female, never-smoker, underwent intracranial surgery for suspected pituitary adenoma. Histopathological assessment of the pituitary lesion and targeted next-generation sequencing (NGS) analysis of single nucleotide variants (SNVs), indels, and copy number variations (CNVs) across 161 unique cancer-associated genes using the Oncomine Comprehensive Assay v3 (Thermo Fisher Scientific, Waltham, MA) revealed instead metastatic pulmonary adenocarcinoma (immunohistochemically CK7+/TTF1+) with the EGFR ex19del p.E746_A750delELREA and negative programmed death ligand-1-expression. Moreover, total-body positron emission tomography-computed tomography (PET-CT) scan detected a tumor in the left lung’s upper lobe and multiple metastases in both lungs, mediastinal lymph nodes, and L2 vertebra, corresponding to T3N2M1c. Figure 1 summarizes the systemic treatments used for the patient.

Stereotactic radiosurgery against the pituitary metastasis was followed by systemic erlotinib treatment. Progression of primary tumor and mediastinal lymph nodal metastases was observed 15 months later. Lymph nodal biopsy and DNA-NGS analysis revealed the original EGFR ex19del and a new EGFR mutation p.T790M. The patient started second-line osimertinib 80 mg once daily. Plasma cell-free DNA (cfDNA) testing (Oncomine Lung cfDNA NGS assay; Thermo Fisher Scientific) at 4, 7, and 13 months of this treatment showed no EGFR mutations. However, two liver metastases were observed after 15 months. DNA-NGS analysis of the biopsy from one of them showed persistent EGFR ex19del and a new EGFR mutation p.T790M. The patient started second-line osimertinib 80 mg once daily. Plasma cell-free DNA (cfDNA) testing (Oncomine Lung cfDNA NGS assay; Thermo Fisher Scientific) at 4, 7, and 13 months of this treatment showed no EGFR mutations. However, two liver metastases were observed after 15 months. DNA-NGS analysis of the biopsy from one of them showed persistent EGFR ex19del and a new EGFR mutation p.T790M, which concomitantly reappeared in plasma cfDNA. Additionally, two putative resistance mechanisms, MDM2 amplification (19 gene copies) and the missense PTEN substitution p.C124S (oncogenic mutation in PTEN phosphatase catalytic domain, according to COSMIC® and OncoKB databases6,7), were identified in this metastasis. Hence, no further targeted treatment options were deemed possible. The patient received three cycles of carboplatin-pemetrexed while continuing osimertinib but could not tolerate more chemotherapy because of bone marrow toxicity.
However, supplementary NGS analysis of RNA from the hepatic metastasis using the Archer FusionPlex Lung kit (ArcherDX Inc, Boulder, CO) showed ANK3-RET fusion on chromosome 10q with break points at positions chr10:61994446 and chr10:43612032, respectively (Fig 2). The Archer Analysis software v.6.2.1 predicted the fusion to be in frame and detected it in 71.5% of reads. According to COSMIC annotations, both break points are outside the two genes’ coding sequence (RET: chr10:43077027-43130351, positive strand; ANK3: chr10:60026298-60389730, negative strand). Furthermore, other genes are present on chromosome 10q between ANK3 and RET, suggesting that the ANK3-RET fusion was intergenic and comprised ANK3 exon 1-8 and RET exon 12-21 with completely preserved RET-kinase domain.

Retrospective NGS of RNA isolated from the pre- osimertinib biopsies (diagnostic pituitary biopsy and tumor rebiopsy at first intrathoracic progression) did not show the ANK3-RET fusion. This confirmed that the latter had been acquired during osimertinib treatment and could explain progression, as other RET fusions have been reported as mechanisms of acquired resistance to EGFR-TKIs.4,8,9 Thus, RET-TKI treatment with pralsetinib 400 mg once daily combined with continuation of osimertinib 80 mg once daily was initiated. After 2 weeks, this combination was shortly paused because of...
interstitial pneumonia, which completely resolved on steroid therapy. The patient resumed the combined TKI treatment at reduced dose (osimertinib 40 mg once daily, pralsetinib 200 mg once daily) without experiencing additional adverse events. The first assessment performed 1 month later revealed a mixed response, with regression of the primary tumor, disappearance of one liver metastasis, and growth of the other one (Figs 3A-3C vs Figs 3D-3F). At the second assessment 4 weeks later, further reduction of primary tumor and regression of both liver metastases were noticed (Figs 3G-3I). Stable disease (SD) in the chest and abdomen was observed after 5 months of treatment (Figs 3J-3L). The following assessments showed complete response in abdomen and slight progression of single pleural lesions, which were biopsied and displayed the PTEN mutation and MDM2 amplification (34 gene copies), but not the pralsetinib-targeted RET fusion. Consequently, to control the pleural lesions, osimertinib dose was reincreased to 80 mg once daily, while pralsetinib 200 mg once daily was maintained. The last PET-CT, so far, performed after 12 months of treatment displayed persisting abdominal complete response and thoracic SD (data not shown). Accordingly, sequential plasma cfDNA did not show reappearance of EGFR mutations during the combination treatment.

The study was conducted according to the Declaration of Helsinki’s guidelines and approved by the Danish Tumor Board Phase I and Lung Team Tumor Board (20200122) at Department of Oncology, Rigshospitalet, University of Copenhagen. Written informed consent for this report was obtained from the patient.
Discussion

Our finding of acquired ANK3-RET fusion as druggable mechanism of osimertinib resistance underlines the importance of including RNA-NGS for gene fusions in clinical practice to find resistance mechanisms and new targeted treatment options. Indeed, the use of complementary RNA-NGS in a prospective genomic profiling of 2,522 lung adenocarcinomas revealed 14% additional actionable gene fusions and METex14 alterations that had not been detected by DNA-NGS. Since detecting RET fusions in plasma cfDNA is challenging, tumor rebiopsies, whenever feasible, should be performed in the setting of EGFR-TKI resistance to identify acquired fusions by RNA-NGS and histologic transformation. Progression on osimertinib due to acquired RET fusions has previously been reported and treated with different multi-modalities, including continuing osimertinib beyond progression, replacing it with the RET-targeting multi-modalities, including osimertinib-pralsetinib combination obtaining an ongoing OR of 4 months. Also combining osimertinib with another RET-TKI, selpercatinib, was effective for a group of EGFR+ NSCLC patients with acquired NCOA4-RET, CCDC6-RET, KIF5B-RET, or RUFY2-RET fusions, as the ORR was 50% and median duration of treatment 7.4 months.

Our case, after progressing on second-line osimertinib, acquired a RET fusion with ANK3, an unreported partner in this setting. After combining osimertinib with pralsetinib, we have obtained an ongoing OR that so far has been maintained for more than 12 months, which, to our knowledge, is the longest reported until now with osimertinib-RET-TKI combinations. The efficacy of these combinations against osimertinib resistance mediated by different RET fusions is noteworthy, that, after initial interruption of the osimertinib-pralsetinib therapy at standard dose because of pulmonary toxicity, we have been able to safely resume and continue the combination at reduced dose of both drugs for 9 months, still obtaining a durable OR. Furthermore, we have reinforced osimertinib to standard dose to control the disease in the chest without causing toxicity. These results may be relevant for patients with acquired resistance mechanisms requiring dual targeted therapy with the risk of overlapping toxicity, as they may still benefit, at least for some time, from a dose reduction of the combined drugs.

Table 1: Summary of Reported Cases Demonstrating Feasibility of Combined EGFR Tyrosine Kinase Inhibitor Plus RET Tyrosine Kinase Inhibitor Treatment for EGFR+ Non-Small-Cell Lung Cancer Patients With Acquired RET Fusions

| Acquired RET-Fusion Type | Treatment Line (EGFR mutation type) | Treatment Used at Progression | Duration of Treatment | References |
|-------------------------|------------------------------------|------------------------------|----------------------|------------|
| ANK3-RET                | Second-line osimertinib (ex19del)  | Osimertinib 40 mg once daily plus pralsetinib 200 mg once daily | 12 months so far     | Current report |
| CCDC6-RET               | Third-line erlotinib (ex19del)    | Cabozantinib 60 mg once daily plus erlotinib 150 mg once daily | 3.5 months          | 9          |
| CCDC6-RET               | Second-line osimertinib (ex19del) | Osimertinib 80 mg once daily plus pralsetinib 300 mg once daily | 4 months so far     | 9          |
| NCOA4-RET               | Second-line osimertinib (ex19del) | Osimertinib 80 mg once daily plus pralsetinib 400 mg once daily | 4 months so far     | 9          |
| CCDC6-RET               | First-line osimertinib (ex19del)  | Osimertinib 80 mg once daily plus selpercatinib 80 mg twice a day | 6 months so far     | 13         |
| CCDC6-RET (n = 5)       | First-line or second-line osimertinib (11 with ex19del; one with L858R) | Osimertinib 80 mg daily (75%, range 40 mg once daily to 80 mg twice a day) plus selpercatinib 80 mg twice a day (92%, range 100 mg once daily to 120 mg twice a day) | Median 7.4 months so far | 14         |
| NCOA4-RET               | First-line afatinib (L858R)       | Afatinib 20 mg once daily plus cabozantinib 20 mg once daily | 7 months so far     | 16         |

Case Report
As DNA-NGS identified MDM2 amplification and PTEN mutation as putative mechanisms of osimertinib resistance and our patient’s permanent steroid replacement for hypophysis insufficiency as well as EGFR+ NSCLC were contraindications for immunotherapy, only chemotherapy could be offered to her. However, complementary RNA-NGS revealed the acquired ANK3-RET fusion, allowing further targeted treatment with combined osimertinib-pralsetinib. Hitherto, 48 different RET fusions have been reported in NSCLC, both as de novo cancer drivers in EGFR wild-type cases and as acquired mechanisms of resistance to osimertinib and other EGFR-TKIs. Notably, de novo ANK3-RET fusion has previously been identified in EGFR wild-type NSCLC, although without any information on response to RET-TKIs. To our knowledge, this is the first report of this fusion as acquired osimertinib-resistance mechanism that can be effectively counteracted by combining pralsetinib with osimertinib continuation. Our report also adds clinically relevant information to the list of intergenic RET rearrangements in NSCLC.

The PTEN mutation and MDM2 amplification occurring in our patient may contribute to TKI resistance. The PTEN substitution has not been described before under osimertinib treatment and may function as parallel resistance mechanism alongside the RET fusion, as the PTEN tumor suppressor inhibits the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathway. The concomitant high-level MDM2 amplification may also promote osimertinib resistance, as MDM2 functions as an E3 ubiquitin ligase targeting the p53 tumor suppressor for proteolysis and antagonizing its transcriptional activity. Indeed, coexisting MDM2 amplification is associated with worse outcome in EGFR-TKI-treated EGFR+ NSCLC. Neither PTEN mutation nor MDM2 amplification were found in the diagnostic biopsy or the first rebiopsy (Fig 1); thus, we considered them as acquired TKI-resistance mechanisms that, together with the ANK3-RET fusion, reflect the clonal heterogeneity of advanced EGFR+ NSCLC at progression on TKIs. Despite preclinical attempts to target MDM2 overexpression and PTEN inactivation, these alterations remain undruggable in clinical practice. Yet, despite such coalterations, our patient’s disseminated NSCLC has been exhibiting a prolonged, ongoing, clinically meaningful response to the pralsetinib-osimertinib combination, further revealing the ANK3-RET fusion as crucial, targetable mechanism of osimertinib resistance.

Accountable for all aspects of the work: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/wc or ascopubs.org/po/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Edyta M. Urbanska
Honorary: AstraZeneca, Roche, Takeda
Consulting or Advisory Role: Amgen, Pfizer, Novartis
Research Funding: Pfizer
Travel, Accommodations, Expenses: Takeda

Jens B. Sørensen
Honorary: AstraZeneca, Roche, Takeda
Consulting or Advisory Role: AstraZeneca, Pfizer, Roche, Takeda

Linea C. Melchior
Honorary: Takeda

Eric Santoni-Rugiu
Honorary: Roche (Inst), Amgen (Inst), Takeda Science Foundation (Inst), AstraZeneca (Inst), Bristol Myers Squibb Foundation (Inst)
Consulting or Advisory Role: Bayer (Inst), Roche (Inst), Takeda, Amgen (Inst)
Travel, Accommodations, Expenses: Takeda

No other potential conflicts of interest were reported.
REFERENCES
1. Santoni-Rugiu E, Melchior LC, Urbanska EM, et al: Intrinsic resistance to EGFR-tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Differences and similarities with acquired resistance. Cancers (Basel) 1:923, 2019
2. Ramalingam SS, Vansteenkiste J, Panchard D, et al: Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 382:41-50, 2020
3. Leonetti A, Sharma S, Minari R, et al: Resistance mechanisms to osimertinib in EGFR-mutant non-small cell lung cancer. Br J Cancer 121:725-737, 2019
4. Olfm M, Somwar R, Rekhtman N, et al: Acquired ALK and RET gene fusions as mechanisms of resistance to Osimertinib in EGFR-mutant lung cancers. JCO Precis Oncol 2:1-12, 2018
5. Zeng L, Yang N, Zhang Y: GOPC-ROS1 rearrangement as an acquired resistance mechanism to osimertinib and responding to crizotinib combined treatments in lung adenocarcinoma. J Thorac Oncol 13:e114-e116, 2018
6. COSMIC, Catalogue of Somatic Mutations in Cancer. https://cancer.sanger.ac.uk/cosmic
7. OncoKB, MSK’s Precision Oncology Knowledge Base. An FDA-Recognized Human Genetic Variant Database. https://www.oncokb.org
8. Klempner SJ, Bazhenova LA, Braiteh FS, et al: Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutant NSCLC-patients who has progressed on first- or second-generation EGFR-TKI. Lung Cancer 89:357-359, 2015
9. Piotrowska Z, Isokahi H, Lennerz JK, et al: Landscape of acquired resistance to Osimertinib in EGFR-mutant NSCLC clinical validation of combined EGFR and RET inhibition with Osimertinib and BLU-667 for acquired RET fusion. Cancer Discov 8:1529-1539, 2018
10. Benayed R, Ofm M, Mullaney K, et al: High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden. Clin Cancer Res 1:4712-4722, 2019
11. Xu H, Shen J, Xiang J, et al: Characterization of acquired receptor tyrosine-kinase fusions as mechanisms of resistance to EGFR tyrosine-kinase inhibitors. Cancer Manag Res 11:6343-6351, 2019
12. Rehman M, Kim C, Reuss JE, et al: Divergent RET- and BRAF-mediated resistance to osimertinib in EGFR-mutant NSCLC: A case report. JCO Precis Oncol 5:939-942, 2021
13. Rich TA, Reckamp KL, Chae YK, et al: Analysis of cell-free DNA from 32,988 advanced cancers reveals novel co-occurring activating RET alterations and oncogenic signaling pathway aberrations. Clin Cancer Res 25:5832-5842, 2019
14. Schoenfeld AJ, Chae YK, Helou M, et al: Combination osimertinib plus selpercatinib for EGFR-mutant non-small cell lung cancer with acquired RET fusions. J Thorac Oncol 16:S230, 2021
15. Melosky B, Juergens R, Hirsh V, et al: Amplifying outcomes: Checkpoint inhibitor combinations in first-line non-small cell lung cancer. Oncologist 25:64-77, 2020
16. Ou S-HI, Zhu VW: Catalog of 5 fusion partners in RET+ NSCLC Circa 2020. JTO Clin Res Rep 1:1-7, 2020
17. Schoenfeld AJ, Chae YK, Helou M, et al: Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to EGFR tyrosine kinase inhibitors. J Thorac Oncol 13:1312-1323, 2018
18. Blakely CM, Watkins TBK, Wu W, et al: Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet 49:1693-1704, 2017
19. Jiang L, Zawacka-Pankau J: The p53/MDM2/MDMX-targeted therapies — A clinical synopsis. Cell Death Dis 11:237, 2020
20. Gkountakos A, Sartori G, Falcone I, et al: PTEN in lung cancer: Dealing with the problem, building on new knowledge and turning the game around. Cancers (Basel) 11:1141, 2019